Pluri (PLUR) Stock Price, News & Analysis

Company Overview

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies. Its PLX cell therapies have been evaluated in clinical studies targeting critical limb ischemia, hematopoietic support following radiation exposure and tissue repair in musculoskeletal injuries. The company has also received grant funding for programs addressing acute radiation syndrome and continues to explore additional indications in immune and inflammatory diseases.

Headquartered in Haifa, Israel, Pluri operates a GMP-certified manufacturing facility capable of supporting commercial-scale production. The company’s global footprint extends to clinical trial sites and partnership agreements in the United States, Europe and the Asia-Pacific region. Pluri’s leadership team brings extensive expertise in regenerative medicine, cellular manufacturing and regulatory affairs as it works toward potential market authorization and broad clinical adoption of its cell therapy products.

Key Stats

• Today's Range: $3.37 to $3.50
• 50-Day Range: $3.05 to $3.67
• 52-Week Range: $2.82 to $6.10
• Volume: 4,567 shs
• Average Volume: 5,989 shs
• Market Capitalization: $37.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Hold

Pluri Stock Analysis - MarketRank™

Pluri scored higher than 34% of companies evaluated by MarketBeat, and ranked 684th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Pluri has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Pluri has a consensus price target of $12.00, representing about 244.8% upside from its current price of $3.48.

Amount of Analyst Coverage

Pluri has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pluri is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pluri is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.32% of the float of Pluri has been sold short.

Short Interest Ratio / Days to Cover

Pluri has a short interest ratio ("days to cover") of 8.46.

Change versus previous month

Short interest in Pluri has recently decreased by 5.03%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pluri does not currently pay a dividend.

Dividend Growth

Pluri does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Pluri this week, compared to 1 article on an average week.

MarketBeat Follows

3 people have added Pluri to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pluri insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.93% of the stock of Pluri is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

16.59% of the stock of Pluri is held by institutions.

Company Calendar

• Last Earnings: 2/12/2026
• Today: 5/09/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PLUR
• CIK: 1158780
• Web: pluri-biotech.com
• Phone: 972747108600
• Fax: 972-74-710-8787
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Pluri: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +244.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.58 million
• Net Margins: -1,890.59%
• Pretax Margin: -1,466.43%
• Return on Equity: N/A
• Return on Assets: -99.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.43
• Quick Ratio: 0.43

Sales & Book Value

• Annual Sales: $1.34 million
• Price / Sales: 27.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.11) per share
• Price / Book: -31.64

Miscellaneous

• Outstanding Shares: 10,770,000
• Free Float: 7,981,000
• Market Cap: $37.48 million
• Optionable: No Data
• Beta: 0.75